Phase 2 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a blood cancer (such as acute leukemia, acute myeloid leukemia, acute lymphoblastic leukemia/lymphoma, or certain types of myelodysplasia), confirmed by a tissue or bone marrow sample
- People aged 60 years or younger at the time of signing consent
- People whose general physical ability and daily functioning meets a minimum health threshold, as measured by standard medical scoring tools (the Karnofsky scale or Lansky play score, depending on age)
- People whose heart, liver, kidneys, and other organs are working well enough to meet the trial's requirements
Who may not be able to join:
- People who are pregnant or breastfeeding
- People who have an active infection that is not under control within one week of starting the preparatory treatment for the trial
- People who are HIV-positive, or who have an active Hepatitis B or C infection with a detectable level of virus in the blood
- People who have previously had a stem cell or bone marrow transplant (either from their own cells or from a donor)
- People whose chronic myeloid leukemia (CML) has progressed to what is known as "blast crisis" stage
- People who have blood cancer that has spread to the central nervous system (brain or spinal cord) and is currently active
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Margaret MacMillan, Masonic Cancer Center, University of Minnesota
Phone: 612-626-2961
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the rate of GVHD after alpha beta TCR depletion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.